Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

First-Line Toripalimab Plus Chemotherapy Elicits Survival Benefit in NSCLC Irrespective of PD-L1 Status

June 9th 2022

Adding toripalimab to chemotherapy in the frontline setting demonstrated improved progression-free survival vs placebo plus chemotherapy in patients with advanced non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 status.

Novel Chemoimmunotherapy Combinations Build on Established Treatment Standards in Lung Cancer

June 9th 2022

Lawrence E. Feldman, MD, discusses shifting standards of care in small cell lung cancer, plus the implications of the phase 3 LEAP-006 and LEAP-008 trials in non–small cell lung cancer.

Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC

June 7th 2022

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions

June 7th 2022

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

June 7th 2022

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC

June 7th 2022

Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.

Latest in Lung, Genitourinary, Gynecologic, and Breast Cancers From ASCO 2022: Drs Charu Aggarwal, Bradley McGregor, Robert Coleman, and Kevin Kalinsky

June 7th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Adjuvant Pembrolizumab Demonstrates DFS Benefit in Key Subgroups of Resected Early-Stage NSCLC

June 7th 2022

Adjuvant pembrolizumab was found to generally improve disease-free survival over placebo in patients with completely resected early-stage non–small cell lung cancer, irrespective of type of surgical resection, tumor size, and type or extent of adjuvant chemotherapy.

Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer

June 6th 2022

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC

June 6th 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.

Pathologic Response Is Key Indicator of EFS Benefit With Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

June 6th 2022

Neoadjuvant nivolumab in combination with platinum-based doublet chemotherapy extended event-free survival in patients with stage IB-IIA non–small cell lung cancer who had pathologic complete response, according to a post hoc analysis of the phase 3 CheckMate 816 trial.

Capmatinib Plus Pembrolizumab Does Not Provide Clinical Benefit in MET Unselected, PD-L1-high Expressing NSCLC

June 6th 2022

The addition of the MET inhibitor capmatinib to pembrolizumab failed to improve clinical outcomes in patients with treatment-naïve non–small cell lung cancer with PD-L1 expression of at least 50% vs pembrolizumab alone, according to an analysis of outcomes of patients in the MET unselected population treated in a phase 2 trial.

Mobocertinib May Have Limited Intracranial Activity in EGFR Exon 20 Insertion+ NSCLC With Baseline Brain Mets

June 6th 2022

Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.

Lurbinectedin Plus Pembrolizumab Produces Early Efficacy Signals in Relapsed Small Cell Lung Cancer

June 6th 2022

The combination of lurbinectedin and pembrolizumab demonstrated preliminary efficacy signals and was shown to be tolerable with a median relative dose intensity exceeding 90% in patients with small cell lung cancer that relapsed on platinum-based chemotherapy, according to findings from the phase 1/2 LUPER study.

Tiragolumab and Atezolizumab Plus Chemotherapy Fails to Improve Survival Outcomes in Extensive-Stage SCLC

June 5th 2022

Tiragolumab combined with atezolizumab plus carboplatin and etoposide demonstrated no additional survival benefits compared with atezolizumab plus chemotherapy alone in patients with treatment-naïve, extensive-stage small cell lung cancer.

Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer

June 5th 2022

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

Preview of ASCO 2022: Dr Everett Vokes

June 5th 2022

CLN-081 Produces Antitumor Activity With Acceptable Safety in Heavily Pretreated EGFR Exon 20 Insertion+ NSCLC

June 3rd 2022

The selective EGFR inhibitor CLN-081 elicited objective responses in heavily pretreated patients with non–small cell lung cancer with EGFR exon 20 insertions and was found to have an acceptable toxicity profile, according to data from the phase 1/2a CLN-081-001 trial.